Michael K. Lee

Active 1988–2025

82
Papers
24,063
Citations
66
h-index
78
i10-index

Citations

Citations per year for Michael K. Lee1951: 1 citations1988: 1 citations1989: 4 citations1990: 8 citations1991: 17 citations1992: 20 citations1993: 16 citations1994: 33 citations1995: 52 citations1996: 140 citations1997: 279 citations1998: 322 citations1999: 317 citations2000: 292 citations2001: 264 citations2002: 336 citations2003: 351 citations2004: 311 citations2005: 283 citations2006: 293 citations2007: 270 citations2008: 302 citations2009: 354 citations2010: 309 citations2011: 321 citations2012: 359 citations2013: 303 citations2014: 271 citations2015: 255 citations2016: 235 citations2017: 246 citations2018: 199 citations2019: 612 citations2020: 651 citations2021: 611 citations2022: 439 citations2023: 330 citations2024: 469 citations2025: 226 citations2026: 4 citations1952–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,117 citing papers, 36.4% of this breakdownChina: 767 citing papers, 6.8% of this breakdownUnited Kingdom: 706 citing papers, 6.2% of this breakdownGermany: 640 citing papers, 5.7% of this breakdownJapan: 477 citing papers, 4.2% of this breakdownCanada: 475 citing papers, 4.2% of this breakdownItaly: 403 citing papers, 3.6% of this breakdownFrance: 370 citing papers, 3.3% of this breakdownSpain: 301 citing papers, 2.7% of this breakdownAustralia: 296 citing papers, 2.6% of this breakdownSwitzerland: 237 citing papers, 2.1% of this breakdownSweden: 205 citing papers, 1.8% of this breakdown
0%36.4%Other 20.4%

Fields

  • Medicine62.1%
  • Biochemistry, Genetics and Molecular Biology22.2%
  • Neuroscience11.7%
  • Immunology and Microbiology1.3%
  • Nursing0.8%
  • Chemistry0.4%
  • Other1.5%

Topics

  • Alzheimer's disease research and treatments12.4%
  • Parkinson's Disease Mechanisms and Treatments9%
  • Amyotrophic Lateral Sclerosis Research4.7%
  • Neuroinflammation and Neurodegeneration Mechanisms3.1%
  • Nuclear Receptors and Signaling2.7%
  • Neuroscience and Neuropharmacology Research2.6%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase

    Authors: , , , , , , , , , , , - Human Molecular Genetics 2003 cited by 1,599

  2. Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

    Authors: , , , , , , , , - Neuron 2010 cited by 1,067

  3. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 cited by 840

  4. α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton

    Authors: , , - Neuron 2017 cited by 235

  5. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Constantine G. Lyketsos, Neuropsychiatric Syndromes Professional Interest Area of ISTAART - Alzheimer s & Dementia 2013 cited by 381

  6. Endoplasmic Reticulum Stress Is Important for the Manifestations of α-SynucleinopathyIn Vivo

    Authors: , , , , , , , - Journal of Neuroscience 2012 cited by 380

  7. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo

    Authors: , , , , , , , , , , , , , , , , , , , - Neuron 1996 cited by 1,485

  8. Accumulation of Toxic α-Synuclein Oligomer within Endoplasmic Reticulum Occurs in α-SynucleinopathyIn Vivo

    Authors: , , , , , - Journal of Neuroscience 2012 cited by 328

  9. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases

    Authors: , , , , , , , , , , , , - Human Molecular Genetics 2007 cited by 445

  10. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions

    Authors: , , , , , , , , , , - Neuron 1997 cited by 1,330

  11. Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 467

  12. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jochen Reiser, Joyce Paras, Michael P. Kane, Eric A. Singer, Jyoti Malhotra, Lisa Denzin, Derek B. Sant’Angelo, Arnold B. Rabson, Leonard Y. Lee, Ahmed Lasfar, John Langenfeld, Jason M. Schenkel, Mary J. Fidler, Emily S. Ruiz, Amanda L. Marzo, Jai S. Rudra, Ann W. Silk, Andrew Zloza - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 191

  13. Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death

    Authors: , , , , , , , - Journal of Neuroscience 2006 cited by 679

  14. Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the α-Synuclein Pathology in a Transgenic Mouse Model of Parkinson’s Disease

    Authors: , - Cells 2021 cited by 56

  15. The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine

    Authors: , , , , , - Journal of Biological Chemistry 1996 cited by 342

  16. Partial inhibition of mitochondrial complex I ameliorates Alzheimer’s disease pathology and cognition in APP/PS1 female mice

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emirhan Nemutlu, Petras P. Dzeja, Adam Jaspersen, Ye In Christopher Kwon, Michael K. Lee, Eugenia Trushina - Communications Biology 2021 cited by 69

  17. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria

    Authors: , , , , , , , , - Neuron 1995 cited by 1,437

  18. Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease

    Authors: , , , , , , , , , - Journal of Neuroscience 2008 cited by 209

  19. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity.

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1994 cited by 628

  20. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy

    Authors: , , , , , , , , , , , , , , - Acta Neuropathologica 2019 cited by 88

  21. α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment

    Authors: , , , , , , , - Molecular Neurodegeneration 2020 cited by 66

  22. Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration

    Authors: , , , - Nature Aging 2024 cited by 28

  23. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins

    Authors: , , , , , , , , - Neuron 1997 cited by 1,030

  24. Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform

    Authors: , , , , , , - Neuron 1999 cited by 560